Cisplatin resistance and pd-l1

Author: mqxt

August undefined, 2024

WebSep 18, 2024 · NCBI Bookshelf WebCisplatin is one of the most effective broad-spectrum anticancer drugs. Its effectiveness seems to be due to the unique properties of cisplatin, which enters cells via multiple …

Comparative study of the PD-L1 expression and CD8+ tumor …

WebNov 23, 2024 · It was reported that the combined administration of anti-PD-L1 antibodies and DDP significantly reduced tumor growth compared with single-agent treatments and controls . These findings indicated a key role of PD-L1 in regulating DDP resistance of cancer cells. The survival and proliferation of cancer cells require the expression of cyclin … WebApr 14, 2024 · Moreover, subsequent experiments revealed that HAT1 upregulates PD-L1 expression through the action of the transcription factor BRD4, which binds to the promoter of PD-L1. ... Notably, during the development of cisplatin resistance, many changes at the genetic and epigenetic levels are evident . HAT1 has been shown to contribute to … daily bugle itar

Investigating PD-1/PD-L1 Checkpoint Inhibition as a …

WebDec 19, 2024 · The differential expression of PD-L1 at the mRNA and protein levels in the chemosensitive and chemoresistant cell lines strongly implicate PD-L1 in the development of cisplatin resistance.... WebSteven G. Gray, in Epigenetic Cancer Therapy, 2015 3.3 EZH2/PRC2 Complexes and Cisplatin Resistance. One of the first indicators that the lysine methyltransferase EZH2 … WebOct 22, 2024 · Cisplatin is an alkylating agent which induces DNA damage through the formation of cisplatin-DNA adducts, leading to cell cycle arrest and apoptosis. In the management of advanced OSCC, cisplatin-based chemotherapy or chemoradiotherapy has been considered as the first-line treatment. biograph machine

Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell ... - PubMed

The relationship between the PD-1/PD-L1 pathway and DNA …

WebMay 28, 2024 · PD-L1 is critical for tumor cell escape from immune surveillance by inhibiting T cell function via the PD-1 receptor. Accumulating evidence demonstrates that anti-PD-L1 monoclonal antibodies might potently enhance antitumor effects in various tumors, but the effect of PD-L1 on colorectal cancer stem cells (CSCs) remains unclear. WebPD-L1 in cancer cells, PD-L1 in TILs, and PD-1 in TILs took up 59.1%, 47.0%, and 60.6%, respectively. The data indicated that both dMMR and PD-L1 overexpression resulted … daily bugle hathttp://mars.gmu.edu/handle/1920/13265?show=full biograph mct.s

"WebPD-L1 increases resistance to radiation or cisplatin by stabilizing NBS1, BRCA1, and other proteins that facilitate the repair of DNA damage ( 5 ). PD-L1 also diminishes IFN-β cytotoxicity by inhibiting an IFN-β–induced STAT3/caspase-7–dependent pathway ( 6 ). " - Cisplatin resistance and pd-l1

Cisplatin resistance and pd-l1

Gastric cancer derived mesenchymal stem cells promoted DNA …

WebApr 10, 2024 · Investigating PD-1/PD-L1 Checkpoint Inhibition as a Treatment for Platinum-Resistant Ovarian Cancer Show simple item record Files in this item Name: Carter_gmu_0883E_ ... Size: 15.07Mb Format: PDF View/ Open This item appears in the following Collection (s) College of Science Show simple item record

Did you know?

WebCisplatin may also cause upregulation of tumor cell PD-L1, which may in part explain the additive antitumor activity of cisplatin and PD-L1/PD-1 blockade. This information will help in interpreting results of ongoing clinical trials combining these agents, and for comparison of potential future therapeutic combinations for the treatment of head ... WebOct 13, 2024 · For example, cisplatin resistance sometimes correlates with the presence of wild type TP53 . ... High expression of CD274/PD-L1 combined with low expression of the histone deacetylase, ...

WebAug 3, 2024 · Background: Non-small cell lung cancer (NSCLC) cells derived intracellular and extracellular programmed cell death ligand 1 (PD-L1) promoted cancer progression and drug resistance, and facilitated tumor immune evasion. However, the detailed molecular mechanisms are still largely unknown. WebPatients were randomized (1:1:1) to receive one of the following treatments: pembrolizumab as a single agent; pembrolizumab, carboplatin or cisplatin, and FU; or cetuximab, carboplatin or ...

Web14 hours ago · Cisplatin treatment does not change the level of expression of EGFR and PD-L1. ... EVs, namely the tetraspanins CD9 and CD81 which are common EV markers … WebGastric cancer derived mesenchymal stem cells promoted DNA repair and cisplatin resistance through up-regulating PD-L1/Rad51 in gastric cancer 设为首页收藏本站

WebImmune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of non–small cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic drugs may improve the efficacy of ICB in mouse tumor models and patients with cancer.

WebCAFs-derived IL-6 could upregulate CXCR7 in esophageal squamous cell carcinoma and promote resistance to cisplatin via the JAK/STAT3 pathway (Qiao ... T cell receptor-mediated activation rapidly induces PD-1 expression. PD-L1/PD-1 can be regulated by the following signaling pathways in the TME: PI3K/AKT pathway, NF-κB pathway, WNT … daily bugle insideWebJul 28, 2024 · PD-L1, the ligand of PD-1, expresses universally and increases in malignant cells [ 8 ]. Recent studies indicated that both PD-1 and PD-L1 contribute to cisplatin … biographonWebSep 9, 2016 · Here we report that cell-intrinsic expression of PD1 and PD-L1, two immune checkpoints, is required for sustained expansion of SCLC cells under cisplatin selection. Indeed, PD1 and PD-L1 were expressed at a higher level in lung cancer cell lines, tumor tissues, and importantly, in SCLC cells resistant to cisplatin (H69R, H82R), when … daily bugle interiorWebCisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells Immune tolerance is one of the leading causes of chemotherapy resistance in carcinoma cases. daily bugle instructionsWebSep 9, 2016 · Here we report that cell-intrinsic expression of PD1 and PD-L1, two immune checkpoints, is required for sustained expansion of SCLC cells under cisplatin … biograph mct flow 64WebMar 15, 2024 · Carboplatin-based regimens — For patients who are otherwise candidates for combination chemotherapy but are unable to receive cisplatin (eg, due to renal dysfunction, neuropathy, severe hearing loss, or heart failure), we suggest the combination of gemcitabine plus carboplatin. daily bugle lego caseWebNov 4, 2024 · Our results suggested blockage of the cell-intrinsic PD-1/PD-L1 maybe the reason why combined PD-1/PD-L1 inhibitors and cisplatin had an increased efficacy in cervical cancer cells. daily bugle lego minifigures